title: Chagas disease research and development: Is there light at the end of the tunnel?
abstract: Chagas disease, or American trypanosomiasis, is the result of infection by the parasiteTrypanosoma cruzi. It is endemic in Latin America, and spreading around the globe due to human migration. Although it was first identified more than a century ago, only two old drugs are available for treatment and a lot of questions related to the disease progression, its pathologies, and not to mention the assessment of treatment efficacy, are subject to debate and remain to be answered. Indeed, the current status of evidence and data available does not allow any absolute statement related to treatment needs and outcome for Chagas patients to be made. Although there has been some new impetus in Research and Development for Chagas disease following recent new clinical trials, there is a scientific requirement to review and challenge the current status of evidence and define basic and clinical research priorities and next steps in the field. This should ensure that the best drugs for Chagas disease are developed, but will require a focused and collaborative effort of the entire Chagas disease research community.
authors.affiliation: Drugs for Neglected Diseases initiative (DND i ), 15 Chemin Louis Dunant, 1202 Geneva, Switzerland.
authors.forename: Eric
authors.initials: E
authors.lastname: Chatelain
keywords: Challenges; Drug discovery and development; Trypanosoma cruzi